The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

BMS announced on Friday that Opdivo (nivolumab) had failed to show superiority to standard chemotherapy as a monotherapy in treatment naïve NSCLC patients, a result which was a huge shock ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Opdivo and Opdivo Qvantig showed similar safety profiles. The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is ...

Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

Opdivo (nivolumab) is an immunotherapy treatment for advanced lung cancer or other cancers that have been resistant to other treatments. Though this is a newer drug, Medicare covers the cost of ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.